Praziquantel in Pregnancy: The Maternal Schistosomiasis Gap
Picture a place where more than 80% of people carry Schistosoma mansoni. Now picture a pregnant woman there being sent home with nothing. Not because the drug is missing, but because nobody wrote down that she should get it. A qualitative study of nine healthcare providers in Tanzania’s Mwanza region found exactly that. The real bottleneck in maternal schistosomiasis is not access to praziquantel in pregnancy. It is the missing policy that tells clinicians to use it. This piece looks at what doctors, pharmacists, and nurses said, and what it means for how programs get built.
Schistosomiasis is a parasitic disease. People catch it when they touch freshwater that carries the larvae of blood flukes. Around Lake Victoria the local picture is bleak. A 2026 qualitative case study in Mwanza region found S. mansoni infection above 80% in the study area, with S. haematobium second. This is not a rare disease there. It is background noise. Yet when a pregnant woman walks into a reproductive and child health clinic, the system has little for her.
Why maternal schistosomiasis matters
Schistosomiasis in pregnancy is not some edge case. The numbers are large. Background estimates cited by the study put about 10 million pregnant women at risk worldwide. In endemic areas, as many as 65 percent of pregnant women may be exposed. The cost is real: babies born underweight die at roughly three times the rate of normal-weight babies, and maternal infection plays a part. None of those figures came from the Mwanza interviews. The study cited them to explain why the topic matters.
About the study: design and participants
The work we are looking at is a 2026 exploratory qualitative case study. It ran in October 2024 across three districts in Mwanza region, Tanzania: Misungwi, Sengerema, and Magu, picked at random. The sites were reproductive and child health clinics in district hospitals. The team did nine in-depth interviews with providers: three doctors, three pharmacists, three nurses. They sampled on purpose and stopped once the interviews stopped surfacing new themes.
The nine were not a uniform group. Six were women. Eight held a bachelor’s degree, one held a nursing certificate. Experience varied: five had ten or more years on the job, four had less than five. The interviews followed a semi-structured guide, drafted in English then translated to Swahili. Two assistants with master’s degrees and qualitative training ran them, in each person’s own office. Each lasted 25 to 45 minutes, was recorded, transcribed word for word, and coded by theme.
Table 1 shows who took part.
| Participant profile | Count |
|---|---|
| Doctors | 3 |
| Pharmacists | 3 |
| Nurses | 3 |
| Female participants | 6 of 9 |
| Bachelor’s degree holders | 8 |
| Nursing certificate holder | 1 |
| Ten or more years of experience | 5 |
| Under five years of experience | 4 |
What the providers said: three levels, eight barriers
The analysis sorted the barriers into three themes, one per level of the system, with eight sub-themes total. That tidy structure is itself a clue. The problems are not random. They line up at the policy level, the facility level, and the community level.
Table 2 lays out the full map.
| Theme | System level | Barrier (sub-theme) |
|---|---|---|
| 1 | Policy and guidelines | Standard treatment guidelines and antenatal care guidelines are silent on maternal schistosomiasis |
| 1 | Policy and guidelines | Pregnant women are excluded from mass drug administration, which targets school-age children |
| 2 | Health facility | Healthcare workers lack experience and awareness of maternal schistosomiasis |
| 2 | Health facility | Providers worry about the safety of praziquantel use in pregnancy |
| 3 | Community | Schistosomiasis health education is inadequate |
| 3 | Community | Misconceptions and poor healthcare-seeking behavior are common |
| 3 | Community | Community drug outlets are used as the first point of care |
| 3 | Community | Praziquantel carries negative perceptions, seen by residents as a “marketing campaign” |
Theme one is where it hurts most. The standard treatment guidelines and the antenatal care guidelines simply never mention maternal schistosomiasis. With no line in the book, frontline staff have no instruction to screen, treat, or refer. The second gap is built into the program design. Mass drug administration pushes praziquantel to school-age children. Pregnant women are not in that group. So the people most exposed in endemic areas miss the one system that reaches them at scale.
Theme two is the facility. Providers said they rarely see maternal schistosomiasis and often feel unsure whether praziquantel is safe in pregnancy. That doubt counts. With no clear guideline, a careful clinician plays it safe and does nothing.
Theme three is the community. Health education on schistosomiasis is thin. People hold wrong ideas and often seek care late or in the wrong place. Many go to a community drug outlet first, not a clinic. And the drug carries baggage: residents often treat medicines handed out in mass campaigns as a sales pitch, which dents trust.
Praziquantel in pregnancy: where the guidelines go silent
Here is the part that should bother program planners. The blocker is not the medicine. Praziquantel is an old, off-patent anthelmintic already bought in huge volumes for schistosomiasis control. The blocker is paperwork: a guideline that never names the disease, an antenatal protocol that never asks about it, and a mass treatment program that by design leaves the pregnant woman in the clinic out.
This flips the usual supply story. In many neglected tropical disease programs people argue about price and supply. Here those are mostly solved. What is missing is the instruction to act. A buyer watching order volumes sees praziquantel moving for school-age MDA, while maternal-health demand sits near zero. Not because the need is small, but because no policy opened the channel.
The study also undercuts a common assumption. Keeping pregnant women out of mass drug administration is usually framed as caution. From the provider interviews it looks different. The exclusion pulls the highest-risk group out of the only large delivery system, with no backup route. A precaution meant to protect ends up leaving women uncovered.
Practical implications for buyers and program teams
The findings give three audiences something concrete to act on.
API procurement teams should watch policy, not just price. Praziquantel order volumes track mass drug administration calendars and guideline updates. When a country adds schistosomiasis screening and treatment to its antenatal care guideline, a steady new demand channel opens. Until then, maternal-health demand is held down by policy, not cost. Watching guideline revisions in endemic countries beats watching tender prices as an early signal.
Public health implementers should treat integration as the main lever. The study points to folding schistosomiasis care into existing antenatal visits instead of standing up parallel systems. Updating the treatment guidelines and training providers on safe use in pregnancy hit theme one and theme two directly. Community education is the third move, aimed at the wrong ideas and the drug-outlet-first habit in theme three.
Formulation developers have a smaller but real opening. If antenatal care integration takes off, demand shifts toward formats that suit pregnant women and routine ANC: single-dose or easy-to-take oral forms, packaging that helps a health worker dispense. This is a demand scenario, not a current spec, and suppliers should check it against each country’s revised guidelines before they commit capacity.
One note on who is writing this. Kaifeng Darui Pharmaceutical publishes it as educational content. The company makes active pharmaceutical ingredients and lists praziquantel among its anthelmintics. No claim about a specific product, specification, or certification appears here. The point is the system gap, not a product.
Limitations of the study
This was a small qualitative study, and the conclusions should be read that way. Nine providers were interviewed. That is enough to saturate their perspectives, not enough to support prevalence estimates, efficacy claims, or p-values. The study reported no dose, no cure rate, no statistical test, and none should be read into it.
Two missing perspectives deserve a plain statement. The pregnant women were not interviewed, nor were their caregivers. Every participant worked in a facility delivering antenatal care, so answers may lean toward what sounds good. The team limited that by sampling across doctors, pharmacists, and nurses rather than one group. The study calls for follow-up implementation research and for piloting praziquantel in antenatal care or mass drug administration. Until those pilots report, routine praziquantel in pregnancy stays a program-design question, not a settled standard of care.
Frequently asked questions
What did the Tanzania study actually find?
The study interviewed nine healthcare providers in Mwanza region and found that maternal schistosomiasis is blocked by three layers of barriers. Policy guidelines stay silent on the condition, facilities lack training and worry about drug safety, and communities misunderstand the disease and distrust the medicine handed out in campaigns.
Is praziquantel approved for use in pregnancy?
The Mwanza study did not assess approval status and reported no efficacy data. What it found is that providers feel uncertain about pregnancy safety and that national guidelines do not address the condition. Safety policy is decided by each country’s regulators and guidelines, not by this qualitative research.
Why are pregnant women excluded from mass drug administration?
Mass drug administration for schistosomiasis mainly targets school-age children, so pregnant women fall outside that cohort by design. The study shows this leaves the most exposed group without an alternative pathway, because antenatal care guidelines also stay silent on screening and treatment. The result is a coverage gap that no other program fills.
How common is schistosomiasis in pregnancy globally?
Published background estimates, cited by the study, suggest around 10 million pregnant women are affected worldwide and up to 65 percent of pregnant women in endemic areas face risk. These figures are global context, not measurements from the Mwanza interviews, and they describe exposure rather than confirmed active infection.
What are the health risks to the baby?
The study cites background evidence that infants born with low birth weight face roughly three times the death risk of normal-weight infants, and maternal infection is among contributors. The Mwanza study itself measured none of these outcomes; it interviewed providers about barriers, not infant health.
What type of study was this?
It was an exploratory qualitative case study conducted in October 2024 across three randomly selected districts in Mwanza region: Misungwi, Sengerema, and Magu. Data came from nine in-depth interviews at reproductive and child health clinics, analyzed thematically. There were no statistics or treatment comparisons.
Who was interviewed?
Nine providers took part: three doctors, three pharmacists, and three nurses. Six were women. Eight held bachelor’s degrees and one held a nursing certificate. Five had ten or more years of experience and four had under five. Sampling was purposive and stopped at data saturation, so the sample reflects provider views, not patient views.
What is the main barrier to treating pregnant women?
The clearest barrier is policy silence. Standard treatment guidelines and antenatal care guidelines do not mention maternal schistosomiasis, and mass drug administration excludes pregnant women. The drug is available, but no instruction tells staff to use it, so the gap is structural rather than about supply.
What do communities believe about praziquantel?
Community members often view medicines distributed through mass campaigns as a kind of sales or marketing activity, which lowers trust. Combined with weak health education and a habit of visiting drug outlets first, this slows appropriate care-seeking for pregnant women with suspected infection, and it also undermines treatment adherence when drugs are finally offered.
How can public health programs fix this?
The study recommends embedding schistosomiasis care into antenatal visits, updating treatment guidelines, training providers on pregnancy-safe use, and strengthening community education. The study also suggests piloting praziquantel within antenatal care or mass drug administration before wider rollout.
What are the study’s limitations?
It interviewed only nine facility-based providers, so results cannot give prevalence or efficacy. Pregnant women and their caregivers were not included, and social desirability bias is possible. The team reduced this by sampling across doctors, pharmacists, and nurses. Implementation research is recommended next.
What should API buyers take from this?
Buyers should track policy and guideline changes in endemic countries as leading demand signals, since maternal-health use is suppressed by policy rather than price. Any shift toward antenatal care integration could open steady new demand for praziquantel, but suppliers should confirm against each country’s revised guidelines.
